THERAPY DOSSIER · th-5d2a988f103a

Sestrin 2 (genetic knockout) and the reactive oxygen species scavenger N-tert-butyl-alpha-phenylnitrone

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23495831 ↗2013Reported benefit

Antioxidant activity of sestrin 2 controls neuropathic pain after peripheral nerve injury.

MouseOtherSestrin 2 knockout (Sesn2-/-) mice and wild-type controls; 129 strain and C57BL backgrounds per MeSH indexingMale and female

Model: Spared nerve injury model of neuropathic pain; acute nociceptive and inflammatory (zymosan) pain models also used

Sesn2 was upregulated in peripheral nerves after spared nerve injury, and Sesn2 knockout mice showed considerably increased late-phase neuropathic pain behaviour with elevated reactive oxygen species and enhanced activating transcription factor 3 upregulation. The exacerbated phenotype was reversed…

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…